At 6.0% CAGR, the Middle East & Africa Clinical Trial Imaging Market is projected to be worth US$ 72.43 million by 2028, says The Business Market Insights 

According to the Business Market Insights’ research, the Middle East & Africa clinical trial imaging market was valued at US$ 54.01 million in 2023 and is expected to reach US$ 72.43 million by 2028, registering a CAGR of 6.0% from 2023 to 2028. AI-Driven clinical trials and in-silico imaging clinical trials are the critical factors attributed to the Middle East & Africa clinical trial imaging market expansion.                    

Artificial Intelligence (AI) aids in effective data collection and management and, thus, acts as a game changer for life science companies involved in the drug development process. The adoption of AI drives innovative ways of collecting clinical trial data and reducing dependency on manual operations. This can be well illustrated by the following used case: AstraZeneca has collected oncology data, including clinical and imaging data, of more than 100,000 consenting patients for different clinical studies. Thus, the increasing application of AI for processing clinical trial data is likely to catalyze the growth of the Middle East & Africa clinical trial imaging market in the coming years.  

On the contrary, high investment and standardized infrastructure requirements hurdles the growth of Middle East & Africa clinical trial imaging market. 

Based on modality, the Middle East & Africa clinical trial imaging market is segmented into tomography, magnetic resonance imaging (MRI), ultrasound, positron emission tomography (pet), x-ray, echocardiography, and others. The tomography segment held 38.2% market share in 2023, amassing US$ 20.62 million. It is projected to garner US$ 27.88 million by 2028 to expand at 6.2% CAGR during 2023–2028.

Based on offering, the Middle East & Africa clinical trial imaging market is segmented into operational imaging services, imaging software, read analysis services, trial design and consulting services, and others. The operational imaging services segment held 33.0% market share in 2023, amassing US$ 17.85 million. It is projected to garner US$ 23.68 million by 2028 to expand at 5.8% CAGR during 2023–2028.

Based on end user the Middle East & Africa clinical trial imaging market is segmented into contract research organizations (CROs), pharmaceutical and biotechnology companies, academic and research institutes, and others. The contract research organizations (CROs) segment held 45.4% market share in 2023, amassing US$ 24.55 million. It is projected to garner US$ 33.21 million by 2028 to expand at 6.2% CAGR during 2023–2028.

Based on country, the Middle East & Africa clinical trial imaging market has been categorized into UAE, Saudi Arabia, South Africa, and Rest of the Middle East & Africa.  Our regional analysis states that South Africa captured 32.5% market share in 2023. It was assessed at US$ 17.53 million in 2023 and is likely to hit US$ 24.07 million by 2028, exhibiting a CAGR of 6.6% during the forecast period.     

Key players dominating the Middle East & Africa clinical trial imaging market are eResearch Technology Inc, ICON PLC, Medical Metrics Inc, VIDA Diagnostics Inc, WCG Clinical Inc among others.   

• In Mar-2023, Clario, a healthcare research technology company that delivers leading endpoint technology solutions for clinical trials, has announced a partnership with Strados Labs to provide the FDA-cleared RESP Biosensor for clinical trials. This innovative, wearable device is lightweight, comfortable and non-invasive, with capabilities that have not previously existed on the market, such as allowing for objective assessment of crackles, rhonchi, and wheeze events, as well as offering a streamlined approach for at-home cough monitoring in trial participants.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com